Breakthrough drugs for the interface between psychiatry and neurology

International Journal of Clinical Practice

Volumn 70, Issue 4, 2016, Pages 298-299

  Citrome, L ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEUTETRABENAZINE; NEUROLEPTIC AGENT; PIMAVANSERIN; PLACEBO; TETRABENAZINE; VALBENAZINE; CENTRAL NERVOUS SYSTEM AGENTS;

BREAKTHROUGH THERAPY STATUS; CLINICAL GLOBAL IMPRESSION SCALE; DRUG RESEARCH; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MOTOR DYSFUNCTION; NEUROLOGY; PARANOIA; PARKINSON DISEASE; PARKINSON DISEASE PSYCHOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PSYCHIATRY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TARDIVE DYSKINESIA; VISUAL HALLUCINATION; NERVOUS SYSTEM DISEASES; PUBLIC RELATIONS;

CENTRAL NERVOUS SYSTEM AGENTS; HUMANS; INTERPROFESSIONAL RELATIONS; NERVOUS SYSTEM DISEASES; NEUROLOGY; PSYCHIATRY;

EID: 84962439287     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12805     Document Type: Editorial

References (17)

1. US Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Guidance for Industry Expedited Programs for Serious Conditions-Drugs and Biologics. May 2014. OMB Control No. 0910-0765. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf (accessed 13 March 2016).
2. Kesselheim AS, Wang B, Franklin JM, Darrow JJ,. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BMJ 2015; 351: h4633.
3. Yandell K,. Picking up the pace. The Scientist. January 2016. http://www.the-scientist.com/?articles.view/articleNo/44773/title/Picking-Up-the-Pace/ (accessed 13 March 2016).
4. Friedman JH,. Parkinson disease psychosis: update. Behav Neurol 2013; 27: 469-77.
5. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R,. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry 2005; 50: 541-7.
6. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L,. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005; 50: 703-14.
7. ™ (Pimavanserin) for Parkinson's Disease Psychosis. Press release September 2, 2014. http://www.businesswire.com/news/home/20140902005293/en/ACADIA-Pharmaceuticals-Receives-FDA-Breakthrough-Therapy-Designation (accessed 13 March 2016).
8. Müller T,. Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opin Investig Drugs 2015; 24: 737-42.
9. Teva Pharmaceuticals. Teva Announces Breakthrough Therapy Designation for SD-809 Granted by FDA for the Treatment of Tardive Dyskinesia. Press release November 9, 2015. http://www.businesswire.com/news/home/20151109005679/en/ (accessed 13 March 2016).
10. Frieling H, Hillemacher T, Ziegenbein M, Neundörfer B, Bleich S,. Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis. Eur Neuropsychopharmacol 2007; 17: 165-71.
11. Raja M, Raja S,. Clozapine safety, 40 years later. Curr Drug Saf 2014; 9: 163-95.
12. Cummings J, Isaacson S, Mills R, et al., Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014; 383: 533-40.
13. Leung JG, Breden EL,. Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother 2011; 45: 525-31.
14. Auspex Pharmaceuticals. Treating Hyperkinetic Movement Disorders. December 2014. http://files.shareholder.com/downloads/AMDA-2IEHYZ/0x0x797219/01a86e01-44d4-4ee0-9fb2-69537c486954/Piper%20Jaffray%20Presentation%2012-2-14.pdf (accessed 13 March 2016).
15. Teva Pharmaceuticals. Teva Advances Pipeline of Movement Disorder Assets with Announcement of Positive Top-Line Data from the First Pivotal Study of Investigational Treatment for Patients with Tardive Dyskinesia. Press release, June 16, 2015. http://www.businesswire.com/news/home/20150616005822/en/Teva-Advances-Pipeline-Movement-Disorder-Assets-Announcement (accessed 13 March 2016).
16. O'Brien CF, Jimenez R, Hauser RA, et al., NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord 2015; 30: 1681-7.
17. Neurocrine Biosciences. Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia. Press release, October 8, 2015. http://www.prnewswire.com/news-releases/neurocrine-announces-positive-results-from-phase-iii-kinect-3-study-of-nbi-98854-in-tardive-dyskinesia-300156384.html (accessed 13 March 2016).